Answer
Sotorasib specifically targets KRAS G12C. A validated tumour test must confirm this mutation because cancers without it are not covered by the licensed indication.
Sources for this answer
- LUMYKRAS 240 mg film-coated tabletsemc · SmPC Current selected SmPC · Version 3